Tandem Diabetes Care Inc (TNDM)

Currency in USD
23.44
+0.63(+2.76%)
Closed·
23.440.00(0.00%)
·
TNDM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.5623.80
52 wk Range
10.2529.65
Key Statistics
Prev. Close
22.81
Open
22.62
Day's Range
22.56-23.8
52 wk Range
10.25-29.65
Volume
1.78M
Average Volume (3m)
2.41M
1-Year Change
111.0761%
Book Value / Share
1.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
TNDM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
28.55
Upside
+21.80%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

Tandem Diabetes Care Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

12 Buy
11 Hold
0 Sell
Ratings:
23 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 28.55
(+21.80% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
RBC Capital
Buy26.00+10.92%30.00MaintainAug 07, 2026
Oppenheimer
Buy22.00-6.14%-MaintainAug 07, 2026
UBS
Hold18.00-23.21%22.00MaintainJul 28, 2026
Mizuho
Hold20.00-14.68%24.00MaintainJul 15, 2026
Deutsche Bank
Hold15.50-33.87%-New CoverageJun 23, 2026

Tandem Diabetes Care Inc SWOT Analysis


Market Challenges
Tandem Diabetes Care faces headwinds in the U.S. market, with recent quarter-over-quarter declines in market share amid fierce competition
Financial Crossroads
Despite robust sales growth, particularly in international markets, Tandem grapples with profitability issues, reflected in negative EPS forecasts
Analyst Perspectives
Price targets range from $10.35 to $53.00, with an average around $30, highlighting diverse views on Tandem's future prospects
Strategic Opportunities
Explore Tandem's product pipeline and international expansion plans, key drivers for potential market share recovery and long-term growth
Read full SWOT analysis

Tandem Diabetes Care Inc Earnings Call Summary for Q2/2026

  • Tandem posted Q2 revenue of $254.6M, up 6% YoY, missing estimates by 0.13%; adjusted EPS of -$0.31 beat forecasts by $0.02.
  • Gross margin hit 57%, second-highest in company history; adjusted EBITDA margin reached 3%, marking fourth consecutive positive quarter.
  • Pharmacy channel gained momentum with 10% of U.S. shipments; company targets 20% of shipments and 15% of revenue by year-end 2026.
  • Full-year guidance reaffirmed at $1.065B-$1.085B revenue; Q3 sales expected at $265M with gross margin dip to 56% before Q4 recovery to 60%.
  • Mobi Tubeless launch expected H2 2026 pending FDA clearance; management sees product as meaningful revenue driver for 2027 and beyond.
Last Updated: 2026-08-06, 05:36 p/m
Read Full Transcript

Earnings

Latest Release
Aug 06, 2026
EPS / Forecast
-0.31 / -0.33
Revenue / Forecast
254.6M / 254.93M
EPS Revisions
Last 90 days

TNDM Income Statement

Compare TNDM to Peers and Sector

Metrics to compare
TNDM
Peers
Sector
Relationship
P/E Ratio
−25.8x−2.9x−0.4x
PEG Ratio
−0.36−0.200.00
Price/Book
12.5x3.5x2.6x
Price / LTM Sales
1.6x2.5x3.1x
Upside (Analyst Target)
16.2%110.5%47.5%
Fair Value Upside
Unlock3.2%5.9%Unlock

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
32.96M48.10%751.92M
Other Institutional Investors
51.73M51.90%1.18B
Public Companies & Retail Investors
0.000.00%0.00
Total
84.7M100.00%1.93B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.60%10,690,844243,858
Sessa Capital IM, L.P.6.90%4,730,757107,909

People Also Watch

215.77
AXSM
-2.32%
16.53
NEO
-0.60%
46.41
VCYT
+0.30%
334.60
NSC
+0.19%
89.24
ARWR
+1.03%

FAQ

What Is the Tandem Diabetes Care (TNDM) Stock Price Today?

The Tandem Diabetes Care stock price today is 23.44 USD.

What Stock Exchange Does Tandem Diabetes Care Trade On?

Tandem Diabetes Care is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Tandem Diabetes Care?

The stock symbol for Tandem Diabetes Care is "TNDM."

What Is the Tandem Diabetes Care Market Cap?

As of today, Tandem Diabetes Care market cap is 1.63B USD.

What Is Tandem Diabetes Care's Earnings Per Share (TTM)?

The Tandem Diabetes Care EPS (TTM) is -0.93.

When Is the Next Tandem Diabetes Care Earnings Date?

Tandem Diabetes Care will release its next earnings report on Nov 04, 2026.

From a Technical Analysis Perspective, Is TNDM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Tandem Diabetes Care Stock Split?

Tandem Diabetes Care has split 1 times.

How Many Employees Does Tandem Diabetes Care Have?

Tandem Diabetes Care has 2500 employees.

What is the current trading status of Tandem Diabetes Care (TNDM)?

As of Aug 12, 2026, Tandem Diabetes Care (TNDM) is trading at a price of 23.44 USD, with a previous close of 22.81 USD. The stock has fluctuated within a day range of 22.56 USD to 23.80 USD, while its 52-week range spans from 10.25 USD to 29.65 USD.

What Is Tandem Diabetes Care (TNDM) Price Target According to Analysts?

The average 12-month price target for Tandem Diabetes Care is 28.55 USD, with a high estimate of 50 USD and a low estimate of 18 USD. 12 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +21.80% Upside potential.

What Is the TNDM Premarket Price?

TNDM's last pre-market stock price is 22.74 USD. The pre-market share volume is 13,740.00, and the stock has decreased by -0.07, or -0.31%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.